当前位置: 首页 >> 检索结果
202. A preinstalled nasopharyngeal airway in the right nasal passageway to facilitate nasogastric intubation in anesthetized and intubated patients: a prospective randomized controlled trial.
Nasogastric intubation (NGI) is usually challenging in patients under general anesthesia, with reported success rate at the first attempt to be less than 50%. The aim of this study was to investigate whether a preinstalled nasopharyngeal airway (NPA) in the right nasal passageway can facilitate NGI in anesthetized and intubated patients.
203. Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial.
作者: Maureen M Leonard.;Jocelyn A Silvester.;Daniel Leffler.;Alessio Fasano.;Ciarán P Kelly.;Suzanne K Lewis.;Jeffrey D Goldsmith.;Elliot Greenblatt.;William W Kwok.;William J McAuliffe.;Kevin Galinsky.;Jenifer Siegelman.;I-Ting Chow.;John A Wagner.;Anna Sapone.;Glennda Smithson.
来源: Gastroenterology. 2021年160卷3期720-733.e8页
Gluten challenge is used to diagnose celiac disease (CeD) and for clinical research. Sustained gluten exposure reliably induces histologic changes but is burdensome. We investigated the relative abilities of multiple biomarkers to assess disease activity induced by 2 gluten doses, and aimed to identify biomarkers to supplement or replace histology.
204. Central Reading of Ulcerative Colitis Clinical Trial Videos Using Neural Networks.
作者: Klaus Gottlieb.;James Requa.;William Karnes.;Ranga Chandra Gudivada.;Jie Shen.;Efren Rael.;Vipin Arora.;Tyler Dao.;Andrew Ninh.;James McGill.
来源: Gastroenterology. 2021年160卷3期710-719.e2页
Endoscopic disease activity scoring in ulcerative colitis (UC) is useful in clinical practice but done infrequently. It is required in clinical trials, where it is expensive and slow because human central readers are needed. A machine learning algorithm automating the process could elevate clinical care and facilitate clinical research. Prior work using single-institution databases and endoscopic still images has been promising.
205. A hypocaloric high-protein diet supplemented with β-cryptoxanthin improves non-alcoholic fatty liver disease: a randomized controlled trial.
作者: Fatemeh Haidari.;Abdollah Hojhabrimanesh.;Bizhan Helli.;Seyed-Saeed Seyedian.;Kambiz Ahmadi-Angali.;Behnaz Abiri.
来源: BMC Gastroenterol. 2020年20卷1期349页
Despite promising animal data, there is no randomized controlled trial (RCT) on the effects of high protein (HP)-diet and/or β-cryptoxanthin in non-alcoholic fatty liver disease (NAFLD).
206. Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy.
作者: Supachaya Sriphoosanaphan.;Kessarin Thanapirom.;Sirinporn Suksawatamnuay.;Panarat Thaimai.;Sukanya Sittisomwong.;Kanokwan Sonsiri.;Nunthiya Srisoonthorn.;Nicha Teeratorn.;Nattaporn Tanpowpong.;Bundit Chaopathomkul.;Sombat Treeprasertsuk.;Yong Poovorawan.;Piyawat Komolmit.
来源: BMC Gastroenterol. 2020年20卷1期346页
Vitamin D (VD) is important in hepatic fibrogenesis in animal models and human studies. VD deficiency is associated with liver fibrosis progression. Metabolic dysfunction of the liver, as an intermediate organ for VD metabolism, contributes partly to this deficiency. We hypothesized that improving hepatic fibrosis and inflammation in chronic hepatitis C (CHC) patients after eradication with direct-acting antivirals (DAA) would increase 25-hydroxyVD [25(OH)VD] levels.
207. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
作者: Elsemieke de Vries.;Ruth Bolier.;Jorn Goet.;Albert Parés.;Jef Verbeek.;Marleen de Vree.;Joost Drenth.;Karel van Erpecum.;Karin van Nieuwkerk.;Frans van der Heide.;Nahid Mostafavi.;Jeltje Helder.;Cyriel Ponsioen.;Ronald Oude Elferink.;Henk van Buuren.;Ulrich Beuers.; .
来源: Gastroenterology. 2021年160卷3期734-743.e6页
Pruritus may seriously impair quality of life in patients with cholestatic diseases such as primary or secondary sclerosing cholangitis (PSC, SSC) and primary biliary cholangitis (PBC). Pharmacologic strategies show limited efficacy and can provoke serious side effects. We hypothesized that bezafibrate, a broad peroxisome proliferator-activated receptor (PPAR) agonist, relieves cholestasis-associated itch by alleviating hepatobiliary injury. The aim of this investigator-initiated FITCH trial (Fibrates for cholestatic ITCH) was to assess effects of bezafibrate on pruritus in patients with PSC, PBC, and SSC.
208. Underwater versus conventional endoscopic mucosal resection for small size non-pedunculated colorectal polyps: a randomized controlled trial : (UEMR vs. CEMR for small size non-pedunculated colorectal polyps).
作者: Zhixin Zhang.;Yonghong Xia.;Hongyao Cui.;Xin Yuan.;Chunnian Wang.;Jiarong Xie.;Yarong Tong.;Weihong Wang.;Lei Xu.
来源: BMC Gastroenterol. 2020年20卷1期311页
Underwater endoscopic mucosal resection (UEMR) is a recently developed technique and can be performed during water-aided or ordinary colonoscopy for the treatment of colorectal polyps. The objective of this clinical trial was to evaluate the efficacy and safety of UEMR in comparison with conventional endoscopic mucosal resection (CEMR) of small non-pedunculated colorectal polyps.
209. Ambulatory Reflux Monitoring Guides Proton Pump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: A Clinical Trial.
作者: Rena Yadlapati.;Melina Masihi.;C Prakash Gyawali.;Dustin A Carlson.;Peter J Kahrilas.;Billy Darren Nix.;Anand Jain.;Joseph R Triggs.;Michael F Vaezi.;Leila Kia.;Alexander Kaizer.;John E Pandolfino.
来源: Gastroenterology. 2021年160卷1期174-182.e1页
Proton pump inhibitor (PPI) therapy fails to provide adequate symptom control in up to 50% of patients with gastroesophageal reflux symptoms. Although a proportion do not require ongoing PPI therapy, a diagnostic approach to identify candidates appropriate for PPI cessation is not available. This study aimed to examine the clinical utility of prolonged wireless reflux monitoring to predict the ability to discontinue PPIs.
210. 99mTc-sodium phytate is a valid alternative to the gold-standard 99mTc-sulfur colloid in the measurement of gastric emptying among healthy multi-ethnic Asian population: results of a randomized cross-over trial.
作者: Norazlina Mat Nawi.;Nashrulhaq Tagiling.;Mohd Fazrin Mohd Rohani.;Wan Mohd Nazlee Wan Zainon.;Muhammad Saifuddin Zanial.;Mung Seong Wong.;Yeong Yeh Lee.
来源: BMC Gastroenterol. 2020年20卷1期293页
It is unclear if the 99mTc-sodium phytate (99mTc-SP) is as reliable as the gold-standard 99mTc-sulfur colloid (99mTc-SC) for gastric emptying scintigraphy (GES). This study is aimed to compare the emptying rates of both radiotracers in a prospective, randomized cross-over trial and to determine the normative data of a healthy multi-ethnic Asian population.
211. Effects of Diet-Modulated Autologous Fecal Microbiota Transplantation on Weight Regain.
作者: Ehud Rinott.;Ilan Youngster.;Anat Yaskolka Meir.;Gal Tsaban.;Hila Zelicha.;Alon Kaplan.;Dan Knights.;Kieran Tuohy.;Francesca Fava.;Matthias Uwe Scholz.;Oren Ziv.;Elad Rubin.;Amir Tirosh.;Assaf Rudich.;Matthias Blüher.;Michael Stumvoll.;Uta Ceglarek.;Karine Clement.;Omry Koren.;Dong D Wang.;Frank B Hu.;Meir J Stampfer.;Iris Shai.
来源: Gastroenterology. 2021年160卷1期158-173.e10页
We evaluated the efficacy and safety of diet-modulated autologous fecal microbiota transplantation (aFMT) for treatment of weight regain after the weight-loss phase.
212. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis.
作者: Katherine Li.;Colleen Marano.;Hongyan Zhang.;Feifei Yang.;William J Sandborn.;Bruce E Sands.;Brian G Feagan.;David T Rubin.;Laurent Peyrin-Biroulet.;Joshua R Friedman.;Gert De Hertogh.
来源: Gastroenterology. 2020年159卷6期2052-2064页
Ustekinumab induces and maintains histologic improvement in patients with ulcerative colitis (UC). The clinical relevance of this endpoint alone, and in combination with endoscopic improvement, is unknown.
213. Efficacy of a high-dose proton pump inhibitor in patients with gastroesophageal reflux disease: a single center, randomized, open-label trial.
作者: Jae Ho Cho.;Cheol Min Shin.;Hyuk Yoon.;Young Soo Park.;Nayoung Kim.;Dong Ho Lee.
来源: BMC Gastroenterol. 2020年20卷1期275页
The extraesophageal manifestations of gastroesophageal reflux disease (GERD) are more difficult to manage than the typical symptoms. The efficacy of high-dose and standard-dose proton pump inhibitors against these atypical symptoms is not yet established.
214. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
作者: Stephen A Harrison.;Guy Neff.;Cynthia D Guy.;Mustafa R Bashir.;Angelo H Paredes.;Juan P Frias.;Ziad Younes.;James F Trotter.;Nadege T Gunn.;Sam E Moussa.;Anita Kohli.;Kristin Nelson.;Mildred Gottwald.;William C G Chang.;Andrew Z Yan.;Alex M DePaoli.;Lei Ling.;Hsiao D Lieu.
来源: Gastroenterology. 2021年160卷1期219-231.e1页
Aldafermin, an engineered analog of fibroblast growth factor 19, inhibits bile acid synthesis and regulates metabolic homeostasis. We report results from a 24-week, phase 2 study, with serial liver biopsies, of patients with nonalcoholic steatohepatitis (NASH).
215. A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.
作者: Matthew R Henn.;Edward J O'Brien.;Liyang Diao.;Brian G Feagan.;William J Sandborn.;Curtis Huttenhower.;Jennifer R Wortman.;Barbara H McGovern.;Sherry Wang-Weigand.;David I Lichter.;Meghan Chafee.;Christopher B Ford.;Patricia Bernardo.;Peng Zhao.;Sheri Simmons.;Amelia D Tomlinson.;David N Cook.;Roger J Pomerantz.;Bharat K Misra.;John G Auninš.;Michele Trucksis.
来源: Gastroenterology. 2021年160卷1期115-127.e30页
Firmicutes bacteria produce metabolites that maintain the intestinal barrier and mucosal immunity. Firmicutes are reduced in the intestinal microbiota of patients with ulcerative colitis (UC). In a phase 1b trial of patients with UC, we evaluated the safety and efficacy of SER-287, an oral formulation of Firmicutes spores, and the effects of vancomycin preconditioning on expansion (engraftment) of SER-287 species in the colon.
216. A randomized crossover trial to assess therapeutic efficacy and cost reduction of acid ursodeoxycholic manufactured by the university hospital for the treatment of primary biliary cholangitis.
作者: Larissa Akeme Nakano.;Eduardo Luiz Rachid Cançado.;Cleuber Esteves Chaves.;Maria Cristina Vaz Madeira.;Jéssica Toshie Katayose.;Mariana Akemi Nabeshima.;Victor Fossaluza.;Gabriela Guimarães Uhrigshardt.;Zheng Liting.;Vanusa Barbosa Pinto.;Flair José Carrilho.;Suzane Kioko Ono.
来源: BMC Gastroenterol. 2020年20卷1期253页
Health care costs are growing faster than the rest of the global economy, according to the World Health Organization (WHO). Countries' health expenditures include paying for general medicine, diagnostic procedures, hospitalizations and surgeries, as well as medications and prescribed treatment. Primary biliary cholangitis (PBC) is a rare autoimmune liver disease and the first line available treatment is ursodeoxycholic acid (UDCA), however, direct and indirect treatment costs are expensive. Main aim of this trial was to assess if the therapeutic efficacy of UDCA manufactured by the university hospital is equivalent to that of standard UDCA and treatment cost reduction in patients with PBC.
217. Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection.
作者: Jessica R Allegretti.;Colleen R Kelly.;Ari Grinspan.;Benjamin H Mullish.;Zain Kassam.;Monika Fischer.
来源: Gastroenterology. 2020年159卷5期1982-1984页 218. Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis.
作者: Alex Straumann.;Alfredo J Lucendo.;Stephan Miehlke.;Michael Vieth.;Christoph Schlag.;Luc Biedermann.;Cecilio Santander Vaquero.;Constanza Ciriza de Los Rios.;Christoph Schmoecker.;Ahmed Madisch.;Petr Hruz.;Jamal Hayat.;Ulrike von Arnim.;Albert Jan Bredenoord.;Stefan Schubert.;Ralph Mueller.;Roland Greinwald.;Alain Schoepfer.;Stephen Attwood.; .
来源: Gastroenterology. 2020年159卷5期1672-1685.e5页
Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder. Swallowed topical-acting corticosteroids are effective in bringing active EoE into remission. However, it is not clear whether these drugs are effective for long-term maintenance of remission.
219. Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial.
作者: Jesse L Carlin.;V Rose Lieberman.;Arya Dahal.;Madison S Keefe.;Changfu Xiao.;Gunther Birznieks.;Thomas L Abell.;Anthony Lembo.;Henry P Parkman.;Mihael H Polymeropoulos.
来源: Gastroenterology. 2021年160卷1期76-87.e4页
Treatments are needed for gastroparesis; antagonists of tachykinin receptor 1 (TACR1, also called NK1R) can reduce symptoms of nausea and vomiting. We investigated the safety and efficacy of tradipitant, an antagonist of NK1R, in patients with idiopathic or diabetic gastroparesis.
220. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
作者: Tom Holvoet.;Marie Joossens.;Jorge F Vázquez-Castellanos.;Evelien Christiaens.;Lander Heyerick.;Jerina Boelens.;Bruno Verhasselt.;Hans van Vlierberghe.;Martine De Vos.;Jeroen Raes.;Danny De Looze.
来源: Gastroenterology. 2021年160卷1期145-157.e8页
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder associated with intestinal dysbiosis. Given the reported promising results of open-label fecal microbiota transplantation (FMT) therapy in patients with predominant abdominal bloating, we studied efficacy of this treatment in a randomized, placebo-controlled trial.
|